Glabellar Frown Lines Clinical Trial
Official title:
A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial With an Open-label Extension Period to Investigate the Efficacy and Safety of IncobotulinumtoxinA (Xeomin), Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines
IncobotulinumtoxinA (Xeomin) is a botulinum toxin type A preparation free of complexing proteins, i.e. free of proteins other than the active toxin. Injected into the muscle, IncobotulinumtoxinA (Xeomin) causes local weakening. Botulinum toxin type A is widely used for aesthetic treatment of facial lines. This study investigated the efficacy and safety of IncobotulinumtoxinA (Xeomin) in the treatment of glabellar frown lines compared to placebo. The study consisted of a Main Period and an Open-Label Extension [OLEX] Period of 120 days each.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02236312 -
Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines
|
Phase 2 | |
| Active, not recruiting |
NCT05565950 -
AI-09 In Subjects With Glabellar Lines, GL-101
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05083286 -
Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines
|
Early Phase 1 | |
| Completed |
NCT03687736 -
Subject Satisfaction With AbobutulinumtoxinA Treatment
|
Phase 4 | |
| Active, not recruiting |
NCT04281745 -
Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX®
|
Phase 4 | |
| Active, not recruiting |
NCT05623410 -
Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines
|
Phase 3 | |
| Active, not recruiting |
NCT03440671 -
The Safety and Efficacy Study of Hutox Versus Botox® in Subject With Moderate to Severe Glabellar Lines
|
Phase 3 | |
| Completed |
NCT03736928 -
Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines
|
Phase 2 | |
| Completed |
NCT01808742 -
Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the CRYO-TOUCH III Device
|
N/A | |
| Completed |
NCT00777803 -
NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines
|
Phase 3 | |
| Completed |
NCT00430586 -
Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines
|
Phase 2 | |
| Completed |
NCT04281095 -
A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines
|
Phase 1/Phase 2 | |
| Completed |
NCT05146999 -
Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines
|
Phase 3 | |
| Completed |
NCT02428608 -
Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006
|
Phase 2 | |
| Completed |
NCT04143815 -
Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines
|
Phase 2 | |
| Not yet recruiting |
NCT05305768 -
Xeomin Treatment of Glabellar Lines Using OLD Versus COLD
|
Early Phase 1 | |
| Completed |
NCT05364580 -
The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines
|
Phase 3 | |
| Completed |
NCT05320393 -
Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines
|
Phase 2 | |
| Completed |
NCT02677805 -
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II
|
Phase 3 | |
| Completed |
NCT01333397 -
Safety and Efficacy Study of Dysport RU and Glabellar Lines
|
Phase 2 |